Skip to main content
S&P 5007,714.17+0.62%DOW51,007.41+0.16%NASDAQ27,176.17+1.13%BTC$85,491.00+1.74%ETH$2,703.21+0.61%GOLD$4,181.30-0.50%OIL$89.84-3.26%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBOT

Microbot Medical Inc.

Healthcare · Medical - Instruments & Supplies

$1.20

Up+$0.02 (+1.67%)

Updated Oct 2, 2026, 2:33 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
108.69M
P/E ratio
-12.46
Dividend yield
0.00%
52-week range
$1.20 – $2.86
Volume
685.51K
Avg. volume
3.35M

Price performance · MBOT

MBOT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

MBOT closed at $1.20 after 20 trading sessions, down 16.67% for the selected period.

Last close
$1.20
Period change
-16.67%
Period low
$1.20
Period high
$1.50
Daily close
View OHLC price history
MBOT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$1.21$1.23$1.18$1.20685.51K
Sep 30, 2026$1.25$1.2595$1.20$1.20518.81K
Sep 29, 2026$1.27$1.28$1.22$1.245631.35K
Sep 28, 2026$1.27$1.28$1.24$1.25424.65K
Sep 25, 2026$1.32$1.33$1.26$1.275485.33K
Sep 24, 2026$1.30$1.32$1.29$1.31310.5K
Sep 23, 2026$1.39$1.39$1.31$1.31461.01K
Sep 22, 2026$1.35$1.39$1.28$1.381.33M
Sep 21, 2026$1.36$1.39$1.34$1.35572.44K
Sep 18, 2026$1.42$1.43$1.35$1.36694.91K
Sep 17, 2026$1.45$1.47$1.42$1.42388.46K
Sep 16, 2026$1.44$1.48$1.43$1.44289.59K
Sep 15, 2026$1.45$1.47$1.43$1.44345.78K
Sep 14, 2026$1.43$1.495$1.42$1.45406.12K
Sep 11, 2026$1.49$1.49$1.44$1.45446.98K
Sep 10, 2026$1.45$1.475$1.45$1.46203.02K
Sep 9, 2026$1.49$1.50$1.45$1.46293.57K
Sep 8, 2026$1.46$1.515$1.45$1.50560.22K
Sep 4, 2026$1.48$1.48$1.44$1.44406.88K
Sep 3, 2026$1.48$1.489$1.44$1.44385.83K

Latest MBOT news

The latest Smart Investors Daily articles mentioning MBOT.

Stock researchCompany · Overview

MBOT research

Overview

Company profile and research snapshot.

Company profile

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
MBOT recent ratings
DateFirmRatingTarget
Aug 14, 2026B. Riley SecuritiesBuy—
Jun 3, 2026LUCID CAPITAL MARKETSBuy—
Apr 14, 2026HC Wainwright & Co.Buy—
Feb 10, 2026B. Riley SecuritiesBuy—
Dec 3, 2025Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 4, 2026

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for he

Yahoo · Mar 3, 2026

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner re

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By